Geoffrey D Barnes, MD, MSc

Associate Professor of Internal Medicine

Associate Chair, Department of Internal Medicine, Medical School

[email protected]

Available to mentor

Geoffrey D Barnes, MD, MSc

Associate Professor

About

Links

Qualifications

Center Memberships

Research Overview

Recent Publications

Manage Your Profile

About

Dr. Barnes is a cardiologist and vascular medicine specialist. His research focuses on developing, implementing, and evaluating antithrombotic stewardship efforts to improve the care of patients with thrombotic conditions and/or those who use anticoagulant medications. He serves as co-director for the Michigan Anticoagulation Quality Improvement Initiative (MAQI2) and as co-director for the Michigan Program on Value Enhancement (MPrOVE). His research is funded by the NIH, AHRQ, and Blue Cross-Blue Shield of Michigan. He serves in leadership roles with several national and International organizations, including the Anticoagulation Forum, American College of Cardiology, and International Society on Thrombosis and Hemostasis. He also serves as the program director for the University of Michigan Vascular Medicine fellowship training program.

Qualifications

Cardiovascular Medicine Fellowship
University of Michigan, Internal Medicine/Cardiovascular Medicine, Ann Arbor, United States
2011 - 2014
Postdoctoral Fellowship

Vascular Medicine Fellowship
University of Michigan, Internal Medicine/Cardiovascular Medicine, Ann Arbor, United States
2013 - 2014
Postdoctoral Fellowship

Internal Medicine Chief Residency
University of Michigan, Internal Medicine, Ann Arbor, United States
2010 - 2011
Chief Resident

Internal Medicine Residency
University of Michigan, Internal Medicine, Ann Arbor, United States
2007 - 2010
Residency

MS
University of Michigan, Ann Arbor, Michigan, United States
2014 - 2015

MD
University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, MI, 48109, United States
2003 - 2007

BS
Washington University in St. Louis, St. Louis, MO, United States
1999 - 2003

Center Memberships

Center Member
AI and Digital Health Innovation
Center Member
Institute for Healthcare Policy and Innovation
Center Member
Center for History, Humanities, Arts, Social Sciences and Ethics in Medicine
Center Member
Samuel and Jean Frankel Cardiovascular Center

Research Overview

Anticoagulation therapy
Venous Thromboembolism
Implementation Science
Quality Improvement
Health systems engineering
Shared decision-making

Recent Publications

See All Publications

Journal Article
Introducing the 2026 Focused Issue on Venous Disease: What excites us most about the future of this field.
Gornik HL, Kanthi Y, McBane RD, Weinberg I, Barnes GD, Piazza G, Vedantham S, Kolluri R. Vasc Med, 2026 Jun; 31 (3): 260 - 263. DOI:10.1177/1358863X261426953
PMID: 42267762
Journal Article
Anticoagulation Services as a Model for Cardiovascular Medication Stewardship.
Barnes GD, Lech T, Allen AL. Circulation, 2026 May 26; 153 (21): 1603 - 1605. DOI:10.1161/CIRCULATIONAHA.126.078166
PMID: 42189956
Journal Article
2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults
Creager MA, Barnes GD, Giri J, Mukherjee D, Jones WS, Burnett AE, Carman T, Casanegra AI, Castellucci LA, Clark SM, Cushman M, de Wit K, Eaves JM, Fang MC, Goldberg JB, Henkin S, Johnston-Cox H, Kadavath S, Kadian-Dodov D, Keeling WB, Klein AJP, Li J, McDaniel MC, Moores LK, Piazza G, Prenger KS, Pugliese SC, Ranade M, Rosovsky RP, Russo F, Secemsky EA, Sista AK, Tefera L, Weinberg I, Westafer LM, Young MN. Journal of the American College of Cardiology, 2026 Apr 7; 87 (13): 1626 - 1710. DOI:10.1016/j.jacc.2025.11.005
PMID: 41712898
Proceeding / Abstract / Poster
26-A-16546-ACC BENCHMARKING TO EVALUATE VARIABILITY IN HEART FAILURE MORTALITY BY RACE AND ETHNICITY IN THE UNITED STATES FROM 2018 TO 2023
Cascino T, Shore S, Barnes GD. Journal of the American College of Cardiology, 2026 Mar 30; 87 (13): a664 DOI:10.1016/j.jacc.2026.02.1745
Journal Article
A Field in Transition
Creager MA, Barnes GD, Giri J. JACC, 2026 Apr 7; 87 (13): 1569 - 1573. DOI:10.1016/j.jacc.2026.01.018
Presentation
Acute PE Management: Case-based Discussion of the 2026 AHA/ACC Acute PE Guidelines
Barnes G. 2026 Apr 17;
Presentation
Case-based Discussion of the 2026 AHA/ACC Acute PE Guidelines
Barnes G. 2026 Apr 21;
Presentation
Case-based Discussion of the 2026 AHA/ACC Acute PE Guidelines
Barnes G. 2026 Apr 21;

Featured News & Stories

Health Lab

Nearly 1 in 6 older adults take aspirin despite no history of heart disease

Around 1 in 6 older adults take aspirin as their primary method of preventing cardiovascular disease, despite stricter guidelines. For some patients, the benefit of aspirin may not outweigh the risk of bleeding.

Health Lab

Reducing dose of popular blood thinners may limit risk of future bleeding

For people taking the popular blood thinners rivaroxaban (brand name Xarelto) and apixaban (brand name Eliquis), after having a blood clot, a reduced dose may limit the future risk of bleeding as well as hospital visits, a Michigan Medicine-led study suggests.

Health Lab

Risk of clots, stroke from incorrect blood thinner dosing reduced using online dashboard

Doctors and pharmacists treating people with blood thinners can now reduce the rate of inappropriate dosing — as well as blood clots and strokes that can result from it — using an electronic patient management system.

person at counter with medicine brown bottle and pills

Health Lab

Most blood thinner dosing problems happen after initial prescription

More than two-thirds of those people take a type of blood thinner called a direct oral anticoagulant. These DOACs, such as rivaroxaban (brand name Xarelto) and apixaban (brand name Eliquis), are under- or over-prescribed in up to one in eight patents. These prescribing issues can have life-threatening consequences, and they most often occur after a provider writes the initial prescription, according to a study led by Michigan Medicine.